Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older
Active, not recruiting · Phase 1, Phase 2 · NCT06686654
Conditions: Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
At a glance
- Research payments reported, 2025
- $17.9M
- U.S. investigators named
- 24
- Sites paid
- 8
- Planned or actual enrollment
- 1,530
About the trial
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Tested
- Investigational hMPV/RSV vaccine (biological), Investigational hMPV vaccine (monovalent) (biological), Investigational RSV vaccine (monovalent) (biological), Licensed RSV Vaccine (biological), Placebo (biological), Investigational RSV+hMPV vaccine (biological)
- Dates
- Started 2024-11-11; completion 2027-01-18
- Results posted
- Not yet
The aim of this study is to evaluate the safety and immunogenicity of a human metapneumovirus (hMPV) / respiratory syncytial virus (RSV) mRNA vaccine candidate encapsulated in a lipid nanoparticle (LNP) based formulation (hereafter referred to as hMPV/RSV vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by hMPV and/or RSV among adults aged 60 years and older. The study will also evaluate the safety and immunogenicity of a booster vaccination using a bivalent hMPV/RSV mRNA vaccine candidate (hereafter referred to as RSV+hMPV mRNA vaccine candidate). Overall, the study is designed to address the following goals: * Assess the safety profile of the candidate formul…
From ClinicalTrials.gov, last updated 2025-12-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi Pasteur Inc. reported $17.9M in research payments for this study in 2025 (475 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Charles S. Plimpton, MD OB-GYN (Obstetrics & Gynecology) · Phoenix, AZ
- Haig A. Goenjian, MD Psychiatry · Long Beach, CA
- David Guzman, M.D. Internal Medicine · Los Angeles, CA
- Stanley Hsia, M.D. Endocrinology & Diabetes · Los Angeles, CA
- Robert A. Jenders Internal Medicine · Torrance, CA
- Ruth E. Kavcioglu, MD Family Medicine · Northridge, CA
- Mark T. Leibowitz, M.D. Internal Medicine · Long Beach, CA
- Jeffrey S. Overcash, MD Emergency Medicine · Chula Vista, CA
- Lawrence D. Sher, M.D. Pediatrics · Rolling Hills Estates, CA
- Robert Williams, M.D. Family Medicine · Golden, CO
- Jorge T. Caso, MD Family Medicine · Miami, FL
- Julio C. Vijil JR., MD, MPH Nephrology (Kidney) · Plantation, FL
- Mark A. Turner, MD Family Medicine · Meridian, ID
- Derrick R. Ward, M.D. Allergy & Immunology · Overland Park, KS
- Shishir K. Khetan, MD Internal Medicine · Rockville, MD
- Brandon J. Essink, M.D. Family Medicine · Creighton, NE
- Jay R. Meyer, MD Emergency Medicine · Lincoln, NE
- Charles H. Eger, M.D Internal Medicine · Cincinnati, OH
- John P. Delgado, MD Family Medicine · Ashland, OR
- Michael P. Zimmerman, M.D. Emergency Medicine · Austin, TX
- John L. Richards, MD Family Medicine · South Jordan, UT
- Thomas A. Piscitelli, D.O. Internal Medicine · North Prince George, VA
- Sofia Teferi, MD Pediatrics · Richmond, VA
- John W. Robinson, M.D. Family Medicine · Edmonds, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Velocity Clinical Research,inc $10.2M
- Velocity Clinical Research $2.9M
- Suncoast Research Associates Llc $2.0M
- Peninsula Headlands Llc $1.7M
- Collaborative Neuroscience Research (cenexel Cns) $718,948
- Suncoast Research Associates, Llc $160,194
- The Children's Mercy Hospital, MO $125,000
- Velocity Clinical Research Inc $49,172
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.